Effects of Chronic Topiramate, Lacosamide, and Levetiracetam Pre-treatment on a Status Epilepticus Model in Rat Pups

In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches

“…105 Another anticonvulsant used for the treatment of seizures and neuropathic pain, lacosamide (Vimpat), decreases neuronal excitability by interaction with two types of molecules: It enhances the slow but not affects fast inactivation of voltage-gated sodium channels, and improves neuronal connectivity via modulation of the activity of collapsin response mediator protein 2 (CRMP-2), although the impact of these mechanisms is not obvious. 106 Nevertheless, neuroprotective effects demonstrated in previous studies [107][108][109] Results of a recently completed clinical trial (NCT01811355) demonstrated that mexiletine (Mexitil, NaMuscla) effectively reduces muscle cramp frequency and severity in ALS patients. 110,111 The mechanism of this drug action is believed to be related to its ability to reduce persistent sodium currents by blocking sodium channels.…”

“…Another anticonvulsant used for the treatment of seizures and neuropathic pain, lacosamide (Vimpat), decreases neuronal excitability by interaction with two types of molecules: It enhances the slow but not affects fast inactivation of voltage‐gated sodium channels, and improves neuronal connectivity via modulation of the activity of collapsin response mediator protein 2 (CRMP‐2), although the impact of these mechanisms is not obvious 106 . Nevertheless, neuroprotective effects demonstrated in previous studies 107–109 stimulated lacosamide testing for the treatment of ALS patients and a Phase I/II open‐label clinical trial (NCT03186040) is ongoing.…”